| Indicators | Browse All

Tyra Biosciences, Inc. (TYRA)

Healthcare | Biotechnology | Carlsbad, United States | NasdaqGS
24.94 USD -1.19 (-4.554%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 24.94

Short-term:★★☆☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 1:05 a.m. EDT

The investment case here is fundamentally broken. Despite a 'strong buy' analyst consensus and a lofty price target, the company is burning cash aggressively with negative free cash flow and negative returns on both assets and equity. The balance sheet shows a massive current ratio of nearly 15x, which masks the reality that the business is not generating operational cash to sustain itself without constant capital infusion. The recent price action confirms this deterioration, with the stock tumbling 46% in the last year despite prior gains. This is a classic value trap where the market has correctly priced out the lack of sustainable growth and profitability. The options market agrees, with traders piling into deep out-of-the-money puts as insurance against further collapse. There is no dividend to provide a floor, and the speculative nature of the biotech sector combined with these financial metrics makes this a dangerous hold for any timeframe.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.089088
AutoARIMA0.089089
MSTL0.089971
AutoTheta0.101106

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 33%
H-stat 17.75
Ljung-Box p 0.000
Jarque-Bera p 0.052
Excess Kurtosis -1.64
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.578
Market Cap 1,483,191,296
Forward P/E -8.42
Beta 0.77
Website https://tyra.bio

As of Aug. 22, 2026, 1:05 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes 15 and 17.5) compared to negligible call volume. While there is some call activity at higher strikes (35 and 40), the overwhelming volume in puts suggests a fear of a significant drop rather than a bet on a rally. Implied volatility is elevated on the put side relative to calls, indicating a skewed risk premium against the stock.


Info Dump

Attribute Value
52 Week Change 1.0853951
Address1 2,656 State Street
All Time High 40.65
All Time Low 4.93
Ask 32.25
Ask Size 2
Audit Risk 5
Average Analyst Rating 1.3 - Strong Buy
Average Daily Volume10 Day 365,950
Average Daily Volume3 Month 784,830
Average Volume 784,830
Average Volume10Days 365,950
Beta 0.766
Bid 25.18
Bid Size 1
Board Risk 7
Book Value 5.928
City Carlsbad
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 9
Country United States
Crypto Tradeable 0
Currency USD
Current Price 24.94
Current Ratio 14.905
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 25.88
Day Low 24.91
Debt To Equity 1.578
Earnings Timestamp End 1,793,822,400
Earnings Timestamp Start 1,793,822,400
Ebitda -159,922,000
Ebitda Margins 0.0
Enterprise To Ebitda -7.128
Enterprise Value 1,139,980,800
Eps Current Year -2.67293
Eps Forward -2.96279
Eps Trailing Twelve Months -2.39
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 29.5461
Fifty Day Average Change -4.6061
Fifty Day Average Change Percent -0.15589537
Fifty Two Week Change Percent 108.53951
Fifty Two Week High 40.65
Fifty Two Week High Change -15.710001
Fifty Two Week High Change Percent -0.38646987
Fifty Two Week Low 11.703
Fifty Two Week Low Change 13.237
Fifty Two Week Low Change Percent 1.1310775
Fifty Two Week Range 11.703 - 40.65
Financial Currency USD
First Trade Date Milliseconds 1,631,712,600,000
Float Shares 35,211,184
Forward Eps -2.96279
Forward P E -8.417742
Free Cashflow -63,067,124
Full Exchange Name NasdaqGS
Full Time Employees 87
Fullday Change -1.19
Fullday Change Percent -4.55415
Fullday Price 24.94
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,785,542,400
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.028499998
Held Percent Institutions 1.17471
Implied Shares Outstanding 59,470,381
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-09-15
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Long Name Tyra Biosciences, Inc.
Market us_market
Market Cap 1,483,191,296
Market State CLOSED
Max Age 86,400
Message Board Id finmb_650787124
Most Recent Quarter 1,782,777,600
Net Income To Common -148,564,992
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 1,556,374,569
Number Of Analyst Opinions 11
Open 25.88
Operating Cashflow -109,651,000
Operating Margins 0.0
Overall Risk 8
Payout Ratio 0.0
Phone 619 728 4760
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 24.94
Post Market Time 1,787,959,806
Previous Close 26.13
Price Eps Current Year -9.330585
Price Hint 2
Price To Book 4.207153
Profit Margins 0.0
Quick Ratio 14.478
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.26667
Region US
Regular Market Change -1.19
Regular Market Change Percent -4.55415
Regular Market Day High 25.88
Regular Market Day Low 24.91
Regular Market Day Range 24.91 - 25.88
Regular Market Open 25.88
Regular Market Previous Close 26.13
Regular Market Price 24.94
Regular Market Time 1,787,947,200
Regular Market Volume 217,472
Return On Assets -0.28456
Return On Equity -0.45306998
Sand P52 Week Change 0.20504117
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 8
Shares Outstanding 59,470,381
Shares Percent Shares Out 0.16239999
Shares Short 9,689,392
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 9,930,770
Short Name Tyra Biosciences, Inc.
Short Percent Of Float 0.29930001
Short Ratio 15.4
Source Interval 15
State CA
Symbol TYRA
Target High Price 59.0
Target Low Price 39.0
Target Mean Price 50.81818
Target Median Price 53.0
Total Cash 353,944,000
Total Cash Per Share 5.931
Total Debt 5,582,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.39
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 30.002476
Two Hundred Day Average Change -5.062475
Two Hundred Day Average Change Percent -0.16873525
Type Disp Equity
Volume 217,472
Website https://tyra.bio
Zip 92,008